Leo’s Law adds a uniform 180‑day extension to several statutory exclusivity and patent‑delay periods under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act for certain orphan drugs whose development was affected by the COVID‑19 emergency. The extension applies only to products that meet a narrow "covered orphan drug" definition tied to applications submitted during the COVID‑19 emergency period and to exclusivity periods that have not yet expired.
The change aims to compensate sponsors for pandemic‑related disruption to clinical development and FDA review timelines, shifting market‑entry dates for competitors and potentially delaying generic and biosimilar competition. For compliance officers and commercial teams, the bill creates a new eligibility test, new calendar calculations tied to the statutory emergency period, and an immediate effective date that does not await FDA guidance.
At a Glance
What It Does
The bill deems specific exclusivity and patent‑related approval‑delay periods extended by 180 days for qualifying orphan drugs, and applies matching extensions to several related statutory terms. Extensions only apply while the original period remains unexpired and target statutory provisions spanning biologic exclusivity, new‑chemical and clinical investigation exclusivities, and orphan exclusivity.
Who It Affects
Drug sponsors with orphan‑designated products that relied on investigational new drug (IND) pathways during the COVID emergency, manufacturers planning generic or biosimilar entry that depend on those exclusivities, and FDA officials who must implement timing determinations. Payers and procurement teams should note shifted loss‑of‑exclusivity dates that affect pricing and formulary decisions.
Why It Matters
This is a narrowly tailored legislative fix that alters the competitive timeline for rare‑disease products without changing approval standards. It creates definitive, statutory calendar adjustments rather than regulatory guidance, which means legal disputes about eligibility and date calculations are likely to be litigated rather than resolved administratively.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Leo’s Law targets a narrow problem: sponsors of orphan drugs that suffered pandemic‑related delays. It does not change approval requirements, safety standards, or the criteria for orphan designation.
Instead, the bill operates by treating certain statutory exclusivity and patent‑delay intervals as if they had 180 extra days tacked on, but only for products that satisfy the bill’s "covered orphan drug" test and only so long as the original exclusivity period has not already expired.
Which statutory terms move on the calendar? The bill names several discrete provisions: the 12‑year biologic exclusivity under section 351(k)(7) of the Public Health Service Act; multiple exclusivity terms in section 505 of the FD&C Act related to new chemical entities and clinical‑investigation‑based exclusivities; the 7‑year orphan exclusivity under section 527(a); and certain patent‑related approval‑delay periods that arise from patent certifications under 505(b)(2) and 505(j).
It also includes a set of "conforming" extensions that match additional alternative durations in those statutes (for example, 4‑year/48‑month variants and a 7.5‑year reference) so the relief lines up with statutory complexity.A product becomes a "covered orphan drug" only if (1) an application was submitted under section 505(i) during the COVID‑19 emergency period, (2) the application ultimately led to approval under the investigational new drug (IND) referenced in that submission (including approvals via 505(b) or 351(a) routes or supplements), and (3) the approved indication is solely for a rare disease or condition (no approved non‑rare indication). The bill defines the COVID‑19 emergency period to begin December 1, 2019, and to end no later than 120 days before the termination of the emergency period defined in section 1135(g)(1)(B) of the Social Security Act, which makes the cutoff date depend on when the Secretary ends the 1135 emergency declaration.Implementation is immediate on enactment and does not require prior FDA rulemaking or guidance.
That immediacy means sponsors, competitors, and payers will need to apply the statute to live exclusivity calendars. Practical consequences include delayed effective dates for competitor approvals that would otherwise rely on the listed exclusivity or patent‑delay periods; potential stacking effects where multiple related statutory periods are each extended; and administrative disputes about whether a given submission qualifies as "submitted under section 505(i) during the COVID–19 emergency period" and whether any relevant exclusivity has already expired.
The Five Things You Need to Know
The bill increases specified exclusivity and patent‑delay periods by exactly 180 days, but only if the original period has not already expired.
Statutory provisions named include the 12‑year biologic exclusivity (PHSA §351(k)(7)(A)), 5‑year and 3‑year FD&C Act exclusivities tied to new chemical entities and clinical investigations (21 U.S.C. 355(c) and (j)), and 7‑year orphan exclusivity (21 U.S.C. 360cc).
A "covered orphan drug" requires (a) a section 505(i) submission filed during the COVID‑19 emergency period, (b) approval tied to the IND referenced in that submission, and (c) no approved non‑rare indication.
The COVID‑19 emergency period is pegged to December 1, 2019 as the start and ends no later than 120 days before termination of the section 1135(g)(1)(B) emergency — making the end date dependent on the Secretary’s termination of that emergency declaration.
The extension is effective upon enactment and applies without waiting for FDA guidance or regulations, which elevates the chance of administrative and judicial disputes over eligibility and date calculations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — "Leo’s Law"
This single provision gives the Act its popular name and carries no substantive effect beyond labeling. It’s useful for citations and for parties drafting agreements and regulatory filings that will reference the statutory relief by name.
Core 180‑day extensions to targeted exclusivities
Subsection (a) is the operational heart of the bill. It identifies the specific exclusivity terms that the statute will treat as extended by 180 days for a qualifying product: the 12‑year biologic exclusivity under PHSA §351(k)(7), several 5‑ and 3‑year exclusivities under FD&C Act §505(c) and §505(j), and the 7‑year orphan exclusivity under §527(a). It also covers certain patent‑related approval‑delay periods tied to patent certifications (the provisions cross‑reference 505(b)(2) and 505(j) certification clauses). The text adds a limiting clause: extensions apply only while the named period is still unexpired, which focuses relief on products still on their exclusivity clock.
Conforming extensions for alternate statutory durations
Subsection (b) aligns parallel statutory terms with the same 180‑day relief. Because the FD&C Act and PHSA contain multiple framed durations (for example, alternate four‑year or 48‑month references and a 7.5‑year entry in some pathways), the bill explicitly extends these corresponding periods so the relief is coherent across different approval pathways and statutory formulations.
Definitions and eligibility gate — covered orphan drug and COVID‑19 emergency period
This subsection defines the eligibility rules. A covered orphan drug links an application filed under 505(i) during the COVID‑19 emergency period to an approval based on the IND tied to that application, and requires that the approved indication be only for a rare disease or condition. The COVID‑19 emergency period wording creates a moving end date: it begins December 1, 2019 and ends not later than 120 days before the statutory section 1135(g)(1)(B) emergency termination, which means the Secretary’s administrative act of ending the 1135 emergency will determine the statutory cutoff. The definition of "corresponding patent‑related approval delay period" ties the extension to the particular patent certification and the last applicable approval date under 505(c)(3) or 505(j)(5)(B).
Immediate effective date
The relief takes effect on the date of enactment and explicitly does not wait for FDA guidance or rulemaking. That choice forces stakeholders to apply the statute directly to exclusivity calendars without an administrative interpretive period, increasing the likelihood of immediate disputes and the need for legal or regulatory interpretation in filings and planning.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Orphan drug sponsors that filed under 505(i) during the COVID emergency: They get up to 180 additional days of market exclusivity or patent‑delay protection for qualifying products, which can meaningfully extend protected revenue windows for small‑patient‑population therapies.
- Biologic developers relying on PHSA §351(k) exclusivity: The explicit mention of the 12‑year biologic exclusivity means some biologic sponsors will see deferred biosimilar entry dates.
- Patient advocacy groups for rare diseases: By lengthening the protected commercial period for some orphan products, the bill seeks to preserve incentives for investment in treatments that might otherwise be delayed or abandoned because of pandemic disruption.
Who Bears the Cost
- Generic and biosimilar applicants (ANDA, 505(b)(2), and biosimilar sponsors): Delayed loss of exclusivity increases the time before they can launch, compressing commercial windows and potentially reducing projected returns.
- Payers and health systems: Extended exclusivity tends to preserve higher branded prices for longer, affecting formulary costs and budget forecasting for insurers and government programs.
- FDA and agency counsel: Immediate statutory application without guidance will produce more eligibility questions, written inquiries, and litigation risk, increasing agency workload and the need for case‑by‑case determinations.
Key Issues
The Core Tension
The bill balances two legitimate goals—preserving incentives for orphan‑drug development disrupted by the pandemic, and maintaining timely entry of lower‑cost generics and biosimilars—but doing so by stretching statutory exclusivity calendars creates winners and losers: it compensates sponsors for pandemic risk while explicitly delaying competitors and prolonging higher prices, and it replaces administrative judgment with statutory deadlines that will invite legal contestation.
The bill is narrowly targeted but raises several implementation and policy questions. First, the dependency of the COVID‑19 emergency period’s end date on the Secretary’s termination of the section 1135(g)(1)(B) emergency makes eligibility dates contingent on an administrative determination that could be litigated or politically fraught.
Second, the statute’s insistence that the extension apply only if the underlying exclusivity has not expired introduces timing haircuts: sponsors and competitors will race to compute whether a period is technically expired as of enactment, producing boundary disputes over what counts as ‘‘expired.’nThird, the interplay between exclusivity extensions and patent‑based approval delays is complex: where both statutory exclusivity and patent stays would block a competitor, the 180‑day additions could stack in unpredictable ways, potentially producing longer net delays than stakeholders expect. That stacking raises questions about whether the relief disproportionately benefits products with layered protections versus those with a single exclusivity term.
Finally, immediate effect without required FDA guidance means courts—not the agency—may be the first to answer core interpretive questions, from what qualifies as a qualifying 505(i) submission to how to calculate the last applicable approval date for patent‑related delays. The absence of an administrative runway increases the prospect of inconsistent decisions across districts and may force expedited litigation or declaratory judgment actions as companies try to lock in launch dates and commercialization plans.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.